Projects

Single Technology Appraisals (STAs), Highly Specialised Technology Appraisals (HSTs) and Cost Comparisons (CCs)

Project Title	Report Status
Elinzanetant for treating moderate to severe vasomotor symptoms associated with menopause	Report due: February 2027 Status: Due to start
Tozorakimab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease	Report due: January 2026 Status: Ongoing
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31)	Report submitted: May 2026 Status: Ongoing
STA Lenacapavir for preventing HIV-1 in people 16 years and over	Report submitted: December 2025 Status: Ongoing
Zuranalone for treating postnatal depression	Report submitted: May 2025 Status: Ongoing
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over	Report submitted: February 2025 Guidance published: 28/05/26
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy	Report submitted: January 2025 Status: Appraisal suspended
Insulin icodec for treating type 2 diabetes	Status: Appraisal suspended until further notice
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer	Report submitted: July 2024 Guidance published: 08/05/2025
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over	Status: Appraisal terminated
Risankizumab for treating moderately to severely active ulcerative colitis	Report submitted: January 2024 Guidance published: 22/08/2024
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome	Report submitted: March 2023 Guidance published: 22/05/2024
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	Report submitted: July 2022 Guidance published: 25/10/2023
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	Report submitted: June 2022 Guidance published: 10/05/2023